MINNEAPOLIS, MN / ACCESSWIRE / April 9, 2015 / PetVivo Holdings, Inc. (PINKSHEETS:PETV) an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices & therapeutics for pets is pleased to announce that the company will be presenting at the 2nd Annual Growth Capital Expo on April 14, 2015 at Caesars Palace in Las Vegas, NV.
Mr. John Lai, Chief Executive Officer of PetVivo Holdings, will provide an overview of the Company's business and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.
Event: Growth Capital Expo
Date: Tuesday, April 14, 2015
Time: 12:00 pm (Pacific Time)
Location: Caesars Palace Resort in Las Vegas
Following Mr. Lai's presentation, Kevin Harrington, one of the original judges on ABC's "Shark Tank" show, will join a panel of active investors in emerging growth companies at the Growth Capital Expo's inaugural Lion's Den pitch.
The Growth Capital Expo brings together the best ideas, the most promising companies and the top deal makers in emerging growth finance for three days of education and networking. The Expo features 500 of the top growth company executives, investors and finance specialists focused on the pre-IPO and public microcap market.
PetVivo Holdings and Gel-Del Technologies previously announced that they have entered into a definitive stock exchange agreement. On March 25th Gel-Del shareholders approved the terms and conditions of the PetVivo merger and authorized the companies management to complete the merger.
About Gel-Del Technologies, Inc.
Gel-Del Technologies (www.gel-del.com) is a biomaterial and medical device manufacturing company based in St. Paul, Minnesota. The company successfully completed a pivotal clinical trial using their novel thermoplastic biomaterial as an injected dermal filler for human facial contour applications (clinicaltrials.gov NCT00414544).
Gel-Del's core competencies include the development and manufacturing of medical devices containing its proprietary biomaterials with or without pharmaceuticals. Using its patented thermoplastic and/or compression manufacturing technologies, purified proteins and carbohydrates are accurately self-assembled and fabricated into cell supporting and tissue compatible biomaterial scaffolds. These "made from scratch" biological scaffolds have the hydrophilic biomimetic structure of the body's non-cellular tissue allowing in vivo biochemical interaction, cellular integration, neovascularization, tissue repair, tissue absorption and regeneration as a temporary or permanent implant. This biomaterial platform has an interlocking proteinaceous structure with inherit molecular forces to contain added components and/or allow their elution for drug delivery at prescribed durations to any body tissue (e.g., transmucosal, injected or implant depots for minutes to months duration).
These non-soluble biomaterials are produced using a patented and reproducible-scalable process that is FDA-validated for human clinical trial production. The inherent properties of these biomaterials allow thermoplastic, compression molding or liquid coating techniques to manufacture implantable devices of all shapes and sizes, including particles for injection and as drug delivery devices at any pharmaceutical dose.
About PetVivo, Inc:
PetVivo, Inc. is a wholly owned subsidiary of PetVivo Holdings, Inc. (PINKSHEETS:PETV) based in Minneapolis, Minnesota. PetVivo is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices and other therapeutics for pets.
PetVivo believes that it can leverage the investments in the human biomaterials and medical device industries to commercialize therapeutics to pets in a capital and time efficient way. PetVivo's strategy is to in-license proprietary products from human medical device companies specifically for use in pets. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals.
Forward-Looking Statements:
The foregoing material may contain forward-looking statements. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements.
CONTACT:
John Lai
Chief Executive Officer
PetVivo Holdings, Inc.
Website: www.petvivo.com
Email: info@petvivo.com
Phone: 612-296-7305
SOURCE: PetVivo Holdings, In